Get started
Allarity Therapeutics, Inc.Allarity Therapeutics, Inc.Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

ALLR chart


Full chart

Key facts today


Allarity Therapeutics, Inc. (ALLR) will start a Phase 2 trial for small cell lung cancer in mid-2025, testing stenoparib with temozolomide, funded by the U.S. Veterans Administration.
Analyze the impactAnalyze the impact

ALLR upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪4.15 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−883.4505 USD
Net income (FY)
‪−11.90 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪3.39 M‬
Beta (1Y)
0.74

Employees


Employees (FY)
6
Change (1Y)
−3 −33.33%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.98 M‬ USD

About Allarity Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Thomas H. Jensen
Website
allarity.com
Headquarters
Boston
Founded
2021
FIGI
BBG012NXCZP8
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ALLR news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ALLR.

Frequently Asked Questions


The current price of ALLR is 0.9369 USD — it has decreased by −9.91% in the past 24 hours. Watch Allarity Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Allarity Therapeutics, Inc. stocks are traded under the ticker ALLR.
ALLR stock has fallen by −10.77% compared to the previous week, the month change is a 15.67% rise, over the last year Allarity Therapeutics, Inc. has showed a −99.51% decrease.
ALLR reached its all-time high on Dec 21, 2021 with the price of 15,288,000.0000 USD, and its all-time low was 0.6775 USD and was reached on Feb 25, 2025. View more price dynamics on ALLR chart.
See other stocks reaching their highest and lowest prices.
ALLR stock is 11.71% volatile and has beta coefficient of 0.74. Track Allarity Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Allarity Therapeutics, Inc. there?
Today Allarity Therapeutics, Inc. has the market capitalization of ‪4.61 M‬, it has increased by 4.00% over the last week.
Yes, you can track Allarity Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Allarity Therapeutics, Inc. is going to release the next earnings report on May 19, 2025. Keep track of upcoming events with our Earnings Calendar.
ALLR earnings for the last quarter are −7.71 USD per share, whereas the estimation was −8.40 USD resulting in a 8.21% surprise. The estimated earnings for the next quarter are −8.10 USD per share. See more details about Allarity Therapeutics, Inc. earnings.
ALLR net income for the last quarter is ‪−11.59 M‬ USD, while the quarter before that showed ‪−1.63 M‬ USD of net income which accounts for −611.48% change. Track more Allarity Therapeutics, Inc. financial stats to get the full picture.
No, ALLR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 1, 2025, the company has 6 employees. See our rating of the largest employees — is Allarity Therapeutics, Inc. on this list?
Like other stocks, ALLR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Allarity Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Allarity Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Allarity Therapeutics, Inc. stock shows the sell signal. See more of Allarity Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.